Tag: PD-L1

Posted on

jhc2026v10i2s10


Original
PD-L1 Immunoexpression in Selected Cases of Lung Carcinoma: A Retrospective Cross-Sectional Study from a Tertiary Care Center in Bangladesh
*Khanam KF,¹ Ayeeda AS,2 Omar T,3 Bhuiyan MT,4 Khanam KA,5  Bhadra S,6Manik MM7

  1. *Dr. Kazi Farzana Khanam, Assistant Professor, Dept. of Pathology, Bangladesh Medical University. kazifarzanabmu@gmail.com. ORCID: https://orcid.org/0009-0005-3496-7337
  2. Dr. Ayesha Sadia Ayeeda, Resident, Phase B, Department of Pathology, Bangladesh Medical University. Ayeeda.ayesha@gmail.com. ORCD: https://orcid.org/0009-0002-6709-3582
  3. Dr. Tasnim Omar, Resident, Phase B, Dept. of Pathology, Bangladesh Medical University. Tasnimomar46@gmail.com. ORCID: https://orcid.org/0009-0006-4947-3759
  4. Dr. Md Abdullah Tareq Bhuiyan, Assistant Professor, Department of Anaesthesiology, Nilphamari Medical College. bhuiyantareqk54@gmail.com. ORCID: https://orcid.org/0009-0004-2766-5296
  5. Dr. Kazi Arhamna Khanam, Resident, Phase B, Depertment of Obstetrics and Gynaecology, Institute of Child and mother health, Dhaka. Arhamna.ilka100@gmail.com. ORCID:  https://orcid.org/0009-0001-7264-0520
  6. Dr. Shima Bhadra, Assistant Professor, Department of Pediatric Pulmonology, Bangladesh Medical University. shimabhadra@gmail.com. ORCD:  https://orcid.org/0009-0008-0367-4357
  7. Dr. Md Mohiuddin Manik, Resident, Phase B, Department of General Surgery, Bangladesh Medical University. manikroyal88@gmail.com. ORCID: https://orcid.org/0009-0007-2101-5905

*For correspondence
Abstract
Background: Programmed death-ligand 1 (PD-L1) is an important predictive biomarker for immune checkpoint inhibitor therapy in non-small cell lung carcinoma (NSCLC). Immunohistochemical assessment of PD-L1 expression has become an essential component in selecting patients for immunotherapy.
Objective: To evaluate PD-L1 immunoexpression in selected cases of lung carcinoma and determine its distribution among different histological subtypes.
Methods: This retrospective cross-sectional study was conducted in the Department of Pathology, Bangladesh Medical University, from 1 June 2025 to 10 June 2026. Thirty-five histopathologically confirmed cases of lung carcinoma in which PD-L1 immunohistochemistry using the PD-L1 (22C3) monoclonal antibody clone had been performed were included. PD-L1 expression was assessed by Tumor Proportion Score (TPS). Data were analyzed using descriptive statistics.
Results: The age of the patients ranged from 40 to 83 years, with a mean age of 60.8 ± 10.9 years. Among the 35 cases, 24 (68.6%) were male and 11 (31.4%) were female. Adenocarcinoma was the most common histological subtype (57.1%), followed by squamous cell carcinoma (34.3%), NSCLC-NOS (5.7%), and adenosquamous carcinoma (2.9%). PD-L1 positivity was observed in 4 (11.4%) cases. Among the positive cases, three were adenocarcinoma and one was NSCLC-NOS. TPS values were 29%, 30%, and 50% in adenocarcinoma cases and 15% in the NSCLC-NOS case. One adenocarcinoma demonstrated high PD-L1 expression (TPS ≥50%).
Conclusion: PD-L1 expression was identified in a small proportion of selected lung carcinoma cases and was predominantly observed in adenocarcinoma. Routine PD-L1 testing may facilitate identification of patients who are likely to benefit from immune checkpoint inhibitor therapy.
[Journal of Histopathology and Cytopathology, 2026 Jul; 10 (2):154-159]
DOI: https://www.doi.org/10.69950/jhc.2026.10.2.10
Full PDF

Posted on

jhc2026v10i2s9


Original
Immunohistochemical Evaluation of PD-L1 Expression in Triple-Negative Breast Cancer: An Analysis of 83 Cases
Alam MM,1 Dey BP,2 *Akhtaruzzaman M,3 Jahan I,4 Nahid MS,5 Rahman MZ6

  1. Dr. Md. Mahabub Alam, Assistant Professor, Department of Pathology, Bangladesh Medical College Hospital, Dhanmondi R/A, Dhaka – 1209, mahabub.robin@gmail.com. ORCID: https://orcid.org/0000-0002-7389-6026
  2. Dr. Bishnu Pada Dey, Associate Professor, Department of Pathology, Bangladesh Medical University, Shahbagh, Dhaka-1000, Bangladesh; drbishnu@bsmmu.edu.bd. ORCID: https://orcid.org/0000-0003-2379-3923
  3. *Dr. Md. Akhtaruzzaman, Clinical Pathologist, Department of Laboratory Medicine, Dhaka Medical College Hospital, Shahbagh, Dhaka-1000, Bangladesh; akter22nd@gmail.com. ORCID: https://orcid.org/0009-0004-9906-8909
  4. Dr. Israt Jahan, Pathologist, 300 bed hospital, Narayanganj-1400, Bangladesh; isratliza424@gmail.com. ORCID: https://orcid.org/0009-0001-4386-8526
  5. Dr. Md. Shahrior Nahid, Assistant professor, Department of Pathology, National Institute of Laboratory Medicine and Referral Centre (NILMRC), Dhaka-1207. shahrior.nahid@gmail.com. ORCID: https://orcid.org/0009-0004-9858-9753
  6. Professor Dr. Md. Zillur Rahman, Professor, Department of Pathology, Bangladesh Medical University, Shahbagh, Dhaka-1000, Bangladesh, drzillur@bsmmu.edu.bd. ORCID: https://orcid.org/0000-0003-3222-1118.

*For correspondence
Abstract
Background: Triple negative breast cancer (TNBC) is an aggressive disease associated with a poorer outcome when compared with other subtypes of breast cancer. Programmed death-ligand 1 (PD-L1) status in TNBC patients has been associated with prognostic value, high PD-L1 expression has reported to predict worse outcomes. PD-1/PD-L1 inhibitors has been approved in the treatment of TNBC in recent times. The aim of this study was to evaluate the expression of PD-L1 in TNBC.
Method:  This was a cross-sectional study conducted among 83 cases of TNBC at the Department of Pathology, Bangladesh Medical University, Dhaka at the period of 2021-2023. Demographic and pathological parameters (histologic type, Nottingham histologic grade, tumor stage etc.) were assessed. Immunohistochemical expression of PD-L1 in tumor cells was observed. Collected data were placed in a data sheet. Results were collected and tabulated. Statistical analysis was performed on the tabulated data by chi-square test using SPSS 25.0.
Result:  PD-L1 expression was positive in 19.3% (16/83) of the cases. Among these 2.4% (2/83) cases were strongly positive. No expression was seen in 80.7% (67/83) of cases.
Conclusion: PD-L1 expression was observed in about one-fifth of the study samples. Therefore, immunotherapy with anti-PD-1/PD-L1 agent can be considered as treatment option in selected TNBC patients.
[Journal of Histopathology and Cytopathology, 2026 Jul; 10 (2):146-153]
DOI: https://www.doi.org/10.69950/jhc.2026.10.2.9
Full PDF

Posted on

jhc.2024.8.1.08

Journal of Histopathology and Cytopathology

January 2024 Volume 8 Issue 1

Original Contribution

Evaluation of PD-L1 Immunoexpression  in Resected Samples of Colorectal Adenocarcinoma: A Study on 64 Cases

1. *Dr. Israt Jahan, Lecturer, Department of Pathology, Chandpur Medical College, Chandpur, Bangladesh; isratliza424@gmail.com
2. Dr. Bishnu Pada Dey, Associate Professor, Department of Pathology, BSMMU, drbishnu@bsmmu.edu.bd
3. Dr. Md. Akhtaruzzaman, Lecturer, Department of Pathology, Pabna Medical College, Pabna, Bangladesh; akter22nd@gmail.com
4. Dr. Kassim Hagi Hussain, Senior lecturer, Department of pathology, Jazeera University Medical College, Somalia; doctorqaasim@gmail.com
5. Dr. Mahabub Alam, Assisstant Professor, Department of Pathology, Bashundhara Ad-din Medical College & Hospital, Dhaka, Bangladesh; mahabub.robin@gmail.com
6. Dr. Md Zillur Rahman, Professor, Department of Pathology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Shahbagh, Dhaka-1000, Bangladesh;drzillur@bsmmu.edu.bd

*For correspondence

Abstract
Background: Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide and its incidence is rising steadily in developing nations. The patient prognosis for CRC remains poor, despite advances in surgery and treatment. Additionally, there are currently no reliable prognostic approaches for CRC, despite the use of conventional prognostic factors. Immune checkpoints blockades (ICB) have emerged as a promising treatment strategy and have dramatically improved long-term survival in several malignances. The “PD-1 (programmed cell death-1)”/PD-L1 (programmed cell death-ligand 1) axis plays an important role to control immune suppression by down-regulating T effector cell activities enable tumor cells to escape from the host’s anti-tumor immune surveillance. Aim of this study was to evaluate the expression of PD-L1 (28-8 clone) in resected samples of colorectal cancer.
Methods: This was a cross-sectional observational study. A total 64 cases were selected from the patients who were diagnosed as adenocarcinoma from resected samples received in the department of pathology at BSMMU from July 2021 to June 2023. Immuno-histochemical staining for PD-L1 was performed along with appropriate positive control.
Results: In this study PD-L1 immuno-expression was found in 14 (21.9%) out of 64 cases. However, no expression was found in rest of the 50 (78.1%) cases.
Conclusion: Evaluation of expression of PD-L1 may emerge as a new marker and target for the immunotherapy of colorectal cancer.

[Journal of Histopathology and Cytopathology, 2024 Jan; 8 (1):56-64]
DOI: https://www.doi.org/10.69950/jhc.2024.v8.i1.08
Keywords: CRC, ICB, PD-1, PD-L1, IRS.

Download Full